0	14	Glucocorticoid	glucocorticoid	NN
15	24	receptors	receptor	NNS
25	27	in	in	IN
28	36	anorexia	anorexia	NN
37	44	nervosa	nervosa	NN
45	48	and	and	CC
49	56	Cushing	cushing	NN
56	58	’s	's	POS
59	66	disease	disease	NN
66	67	.	.	.

69	79	BACKGROUND	background	NN
79	80	:	:	:
81	89	Patients	patient	NNS
90	94	with	with	IN
95	103	anorexia	anorexia	NN
104	111	nervosa	nervosa	NN
112	114	do	do	VBP
115	118	not	not	RB
119	126	display	display	VB
127	137	cushingoid	cushingoid	JJ
138	146	features	feature	NNS
147	149	in	in	IN
150	155	spite	spite	NN
156	158	of	of	IN
159	167	elevated	elevated	JJ
168	176	cortisol	cortisol	NN
177	183	plasma	plasma	NN
184	190	levels	level	NNS
190	191	.	.	.

192	199	Whether	whether	IN
200	201	a	a	DT
202	210	cortisol	cortisol	NN
211	221	resistance	resistance	NN
222	224	or	or	CC
225	226	a	a	DT
227	234	reduced	reduce	VBN
235	247	availability	availability	NN
248	250	of	of	IN
251	254	the	the	DT
255	264	metabolic	metabolic	JJ
265	275	substrates	substrate	NNS
276	285	necessary	necessary	JJ
286	288	to	to	TO
289	296	develop	develop	VB
297	300	the	the	DT
301	307	effect	effect	NN
308	310	of	of	IN
311	326	glucocorticoids	glucocorticoid	NNS
327	329	is	be	VBZ
330	341	responsible	responsible	JJ
342	345	for	for	IN
346	350	this	this	DT
351	354	has	have	VBZ
355	358	not	not	RB
359	363	been	be	VBN
364	375	established	establish	VBN
375	376	.	.	.

377	384	METHODS	methods	NNS
384	385	:	:	:
386	396	Twenty-two	twenty-two	CD
397	405	patients	patient	NNS
406	410	with	with	IN
411	417	severe	severe	JJ
418	429	restrictive	restrictive	JJ
430	438	anorexia	anorexia	NN
439	446	nervosa	nervosa	NN
446	447	,	,	,
448	450	10	10	CD
451	459	patients	patient	NNS
460	464	with	with	IN
465	471	active	active	JJ
472	479	Cushing	cushing	NN
479	481	’s	's	POS
482	489	disease	disease	NN
489	490	,	,	,
491	494	and	and	CC
495	497	24	24	CD
498	505	healthy	healthy	JJ
506	516	volunteers	volunteer	NNS
517	524	without	without	IN
525	536	psychiatric	psychiatric	JJ
537	546	disorders	disorder	NNS
547	549	or	or	CC
550	554	mood	mood	NN
555	566	alterations	alteration	NNS
567	571	were	be	VBD
572	584	investigated	investigate	VBN
584	585	.	.	.

586	600	Glucocorticoid	glucocorticoid	NN
601	609	receptor	receptor	NN
610	625	characteristics	characteristic	NNS
626	630	were	be	VBD
631	639	examined	examine	VBN
640	642	on	on	IN
643	654	mononuclear	mononuclear	JJ
655	665	leukocytes	leukocyte	NNS
666	668	by	by	IN
669	678	measuring	measure	VBG
679	680	[	[	(
680	696	3H]dexamethasone	3H]dexamethasone	NNP
697	704	binding	binding	NN
705	708	and	and	CC
709	712	the	the	DT
713	719	effect	effect	NN
720	722	of	of	IN
723	736	dexamethasone	dexamethasone	NN
737	739	on	on	IN
740	741	[	[	(
741	753	3H]thymidine	3H]thymidine	NNP
754	767	incorporation	incorporation	NN
767	768	,	,	,
769	774	which	which	WDT
775	785	represents	represent	VBZ
786	788	an	an	DT
789	794	index	index	NN
795	797	of	of	IN
798	801	DNA	DNA	NNP
802	811	synthesis	synthesis	NN
811	812	.	.	.

813	820	RESULTS	results	NNS
820	821	:	:	:
822	825	The	the	DT
826	832	number	number	NN
833	835	of	of	IN
836	850	glucocorticoid	glucocorticoid	NN
851	860	receptors	receptor	NNS
861	863	on	on	IN
864	875	mononuclear	mononuclear	JJ
876	886	leukocytes	leukocyte	NNS
887	888	(	(	(
888	891	MNL	MNL	NNP
891	892	)	)	)
893	896	was	be	VBD
897	907	comparable	comparable	JJ
908	910	in	in	IN
911	919	patients	patient	NNS
920	924	with	with	IN
925	933	anorexia	anorexia	NN
934	941	nervosa	nervosa	NN
941	942	,	,	,
943	951	patients	patient	NNS
952	956	with	with	IN
957	963	active	active	JJ
964	971	Cushing	cushing	NN
971	973	’s	's	POS
974	981	disease	disease	NN
981	982	,	,	,
983	986	and	and	CC
987	993	normal	normal	JJ
994	1002	subjects	subject	NNS
1003	1004	(	(	(
1004	1011	binding	binding	NN
1012	1020	capacity	capacity	NN
1021	1024	3.3	3.3	CD
1025	1028	+/-	+/-	SYM
1029	1033	0.23	0.23	CD
1034	1037	vs.	vs.	IN
1038	1041	3.7	3.7	CD
1042	1045	+/-	+/-	SYM
1046	1050	0.30	0.30	CD
1051	1054	and	and	CC
1055	1058	3.5	3.5	CD
1059	1062	+/-	+/-	SYM
1063	1067	0.20	0.20	CD
1068	1078	fmol/10(6)	fmol/10(6)	NN
1079	1084	cells	cell	NNS
1084	1085	)	)	)
1085	1086	.	.	.

1087	1097	Conversely	conversely	RB
1097	1098	,	,	,
1099	1113	glucocorticoid	glucocorticoid	NN
1114	1122	receptor	receptor	NN
1123	1131	affinity	affinity	NN
1132	1135	was	be	VBD
1136	1149	significantly	significantly	RB
1150	1159	decreased	decrease	VBN
1160	1162	in	in	IN
1163	1171	anorexia	anorexia	NN
1172	1179	nervosa	nervosa	NN
1180	1182	as	as	RB
1183	1187	well	well	RB
1188	1190	as	as	IN
1191	1193	in	in	IN
1194	1201	Cushing	cushing	NN
1201	1203	’s	's	POS
1204	1212	patients	patient	NNS
1213	1221	compared	compare	VBN
1222	1224	to	to	TO
1225	1232	control	control	JJ
1233	1241	subjects	subject	NNS
1242	1243	(	(	(
1243	1255	dissociation	dissociation	NN
1256	1264	constant	constant	NN
1265	1268	4.0	4.0	CD
1269	1272	+/-	+/-	CC
1273	1277	0.31	0.31	CD
1278	1281	and	and	CC
1282	1285	4.1	4.1	CD
1286	1289	+/-	+/-	SYM
1290	1294	0.34	0.34	CD
1295	1298	vs.	vs.	IN
1299	1302	2.9	2.9	CD
1303	1306	+/-	+/-	SYM
1307	1311	0.29	0.29	CD
1312	1318	nmol/L	nmol/l	NN
1318	1319	,	,	,
1320	1321	p	p	NN
1322	1323	<	<	SYM
1324	1328	.001	.001	CD
1328	1329	)	)	)
1330	1333	and	and	CC
1334	1343	inversely	inversely	RB
1344	1354	correlated	correlate	VBD
1355	1359	with	with	IN
1360	1363	the	the	DT
1364	1370	levels	level	NNS
1371	1373	of	of	IN
1374	1381	urinary	urinary	JJ
1382	1386	free	free	JJ
1387	1395	cortisol	cortisol	NN
1396	1398	in	in	IN
1399	1403	both	both	DT
1404	1410	groups	group	NNS
1411	1413	of	of	IN
1414	1422	patients	patient	NNS
1422	1423	.	.	.

1424	1429	Basal	basal	JJ
1430	1431	[	[	(
1431	1443	3H]thymidine	3H]thymidine	NNP
1444	1457	incorporation	incorporation	NN
1458	1460	in	in	IN
1461	1464	MNL	MNL	NNP
1465	1468	was	be	VBD
1469	1482	significantly	significantly	RB
1483	1490	reduced	reduce	VBN
1491	1493	in	in	IN
1494	1502	anorexia	anorexia	NN
1503	1510	nervosa	nervosa	NN
1511	1513	as	as	RB
1514	1518	well	well	RB
1519	1521	as	as	IN
1522	1524	in	in	IN
1525	1532	Cushing	cushing	NN
1532	1534	’s	's	POS
1535	1543	patients	patient	NNS
1544	1552	compared	compare	VBN
1553	1555	to	to	TO
1556	1563	control	control	JJ
1564	1572	subjects	subject	NNS
1573	1574	(	(	(
1574	1575	p	p	NN
1576	1577	<	<	JJR
1578	1582	.001	.001	CD
1582	1583	)	)	)
1584	1587	and	and	CC
1588	1591	was	be	VBD
1592	1602	diminished	diminish	VBN
1603	1605	by	by	IN
1606	1619	dexamethasone	dexamethasone	NN
1620	1622	to	to	TO
1623	1625	an	an	DT
1626	1632	extent	extent	NN
1633	1640	similar	similar	JJ
1641	1643	to	to	TO
1644	1651	control	control	JJ
1652	1660	subjects	subject	NNS
1661	1663	in	in	IN
1664	1672	patients	patient	NNS
1673	1677	with	with	IN
1678	1686	anorexia	anorexia	NN
1687	1694	nervosa	nervosa	NN
1694	1695	,	,	,
1696	1699	but	but	CC
1700	1713	significantly	significantly	RB
1714	1715	(	(	(
1715	1716	p	p	NN
1717	1718	<	<	JJR
1719	1723	.001	.001	CD
1723	1724	)	)	)
1725	1729	less	less	RBR
1730	1732	in	in	IN
1733	1738	those	those	DT
1739	1743	with	with	IN
1744	1751	Cushing	cushing	NN
1751	1753	’s	's	POS
1754	1761	disease	disease	NN
1761	1762	.	.	.

1763	1765	In	in	IN
1766	1774	patients	patient	NNS
1775	1779	with	with	IN
1780	1788	anorexia	anorexia	NN
1789	1796	nervosa	nervosa	NN
1796	1797	,	,	,
1798	1801	the	the	DT
1802	1815	incorporation	incorporation	NN
1816	1818	of	of	IN
1819	1820	[	[	(
1820	1832	3H]thymidine	3H]thymidine	NNP
1833	1837	into	into	IN
1838	1841	the	the	DT
1842	1845	MNL	MNL	NNP
1846	1849	was	be	VBD
1850	1859	inversely	inversely	RB
1860	1870	correlated	correlate	VBN
1871	1875	with	with	IN
1876	1883	urinary	urinary	JJ
1884	1888	free	free	JJ
1889	1897	cortisol	cortisol	NN
1898	1904	levels	level	NNS
1904	1905	.	.	.

1906	1917	CONCLUSIONS	conclusions	NNS
1917	1918	:	:	:
1919	1924	These	these	DT
1925	1929	data	datum	NNS
1930	1938	indicate	indicate	VBP
1939	1943	that	that	IN
1944	1947	the	the	DT
1948	1952	lack	lack	NN
1953	1955	of	of	IN
1956	1966	cushingoid	cushingoid	JJ
1967	1975	features	feature	NNS
1976	1978	in	in	IN
1979	1987	patients	patient	NNS
1988	1992	with	with	IN
1993	2001	anorexia	anorexia	NN
2002	2009	nervosa	nervosa	NN
2010	2012	is	be	VBZ
2013	2016	not	not	RB
2017	2027	ascribable	ascribable	JJ
2028	2030	to	to	TO
2031	2032	a	a	DT
2033	2040	reduced	reduce	VBN
2041	2052	sensitivity	sensitivity	NN
2053	2055	to	to	TO
2056	2071	glucocorticoids	glucocorticoid	NNS
2072	2075	but	but	CC
2076	2078	is	be	VBZ
2079	2083	more	more	RBR
2084	2090	likely	likely	JJ
2091	2094	due	due	IN
2095	2097	to	to	TO
2098	2101	the	the	DT
2102	2109	paucity	paucity	NN
2110	2112	of	of	IN
2113	2122	metabolic	metabolic	JJ
2123	2133	substrates	substrate	NNS
2133	2134	.	.	.